The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year. The label now includes three-year data from the AURORA 2 double-blind, placebo-controlled extension study, which assessed the long-term safety and tolerability of LUPKYNIS in combination with mycophenolate mofetil (MMF) and low-dose glucocorticoids, compared with MMF and low-dose glucocorticoids alone, in adults with active lupus nephritis (LN) who completed the Phase 3 AURORA 1 clinical trial.
FDA Approves Updated LUPKYNIS (voclosporin) Label To Include Long-Term Data From The AURORA Clinical Program
Company Profile
Tue. 30 Apr 2024, 6:13am ET
Benzinga
News, Health Care, General